ADG126 (muzasilagot) is a fully human anti-CTLA-4 IgG1 SAFEbody® that is designed to allow preferential activation in the tumor microenvironment [TME] which enables prolonged on-tumor drug exposure and limited systemic toxicity, affording enhanced therapeutic index (TI). Activated ADG126 binds to a unique anti-CTLA-4 epitope to prime T cells and deplete immunosuppressive Tregs through strong antibody-dependent cellular cytotoxicity (ADCC)/phagocytosis (ADCP). Preclinical studies showed that ADG126 (anti-POD) combination effectively increases Teff/Treg ratio. In early Phase I/II studies, ADG126 demonstrated a safety profile and clinical efficacy as monotherapy and in combination with anti-PD-1 therapy.

Here we report the interim results of study ADG126-P001 (a combination study of ADG126 with pembrolizumab, NCT04055955).

- The safety profile of patients (Pts) in dose escalation (all comers, N=11) and the dose expansion (N=24).
- Clinical activity summary of the dose escalation cohort and an in-depth analysis of MSS CRC Pts in dose expansion cohorts.

**Methods and Study Design Schema**

This is a Phase 1/2, open-label, multicenter dose escalation (DE) and expansion (EXP) study of ADG126 in combination with pembrolizumab. Key inclusion criteria are:

1. Advanced or metastatic solid tumors who have progressed after all standard therapies, or for whom no standard therapy is available.
2. Adequate organ and marrow function.

The study design scheme for the dose escalation (DE) and dose expansion (EXP) MSS CRC cohorts is shown below:

**Clinical Activity of Evaluable Patients**

**Case Study: Confirmed Partial Response and Shrinkage of New Liver Lesions in a 3L MSS CRC Patient**

**Female, 66 years old, advanced rectal adenocarcinoma**

**Tumor Type:** MSS CRC

**Prior Therapies:**
- Previously treated with Q3W pembrolizumab
- Previously treated with Nivolumab

**Dose Regimen:**
- ADG126 10 mg/kg Q3W + Pembrolizumab 200 mg Q6W [cytotoxic]

**Dosage Escalation (DE)**

**Dose Expansion (EXP)**

**Clinical Efficacy of Patients with MSS CRC (Free of Liver Metastasis) [N = 48] in Dose Expansion**